BoneSupport granted FDA Approval for Injectable Bone Substitute

BoneSupport AB has been granted FDA approval for its first product, Cerament Bone Void Filler, a ceramic and injectable bone substitute used for among other things bone fractures caused by osteoporosis

This approval allows US clinicians to treat their patients' bone loss due to trauma and surgery. Cerament facilitates the healing and deposition of new bone tissue, and is gradually replaced by the body's own bone.

BoneSupport's synthetically manufactured bone material is tissue-friendly and mixable with radiocontrast liquid, and can therefore be injected to set in place in the skeleton. Cerament Bone Void Filler penetrates and reinforces bone, while allowing for future bone ingrowth.

More than one million bone graft procedures are carried out annually on a global basis. Human and animal bone is primarily used, but the share of synthetic bone substitutes is predicted to rise significantly. The economic value of the total market amounts to about EUR 0.9 billion, with an annual growth rate of 20%.

For further information please contact:

Fredrik Lindberg,

CEO

Tel. +46 46 286 53 70

Email: info@bonesupport.com

Or visit: www.bonesupport.com